🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Venus Remedies Limited VENUSREM NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.venusremedies.com
Company Profile ↓
₹1,935.00
+315.86% 1Y
Mkt Cap₹2,586.51 Cr
P/E25.17
P/B3.64
Div. Yield0.58%
52W High₹1,947.00
52W Low₹431.30
Book Value₹496.56
EPS (TTM)₹76.89

Company Overview

Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, and solvent products, as well as herbal medicine. The company was incorporated in 1989 and is headquartered in Panchkula, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 15.5%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 19.4%.

Consistent Profit Growth

Net profit has compounded at 57.0% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 11.6% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 25.2, below the sector median of 40.0.

Healthy Margins

Operating margin of 15.8% supports profitability.

Recent Developments

  • Mar 2026 Revenue of ₹769.60 Cr (+17.9% YoY); net profit ₹102.78 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +17.9%, earnings +126.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 11.6%, profit CAGR 57.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:11.62%
1 Year:17.88%

Compounded Profit Growth

5 Years:56.99%
1 Year:126.84%

Stock Price Performance

1 Year:+315.86%
6 Months:+159.98%
3 Months:+81.00%
1 Month:+2.76%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 99% of range
₹431.30 ₹1,947.00
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)66.67 · Neutral
Price Performance
1M+2.76%
3M+81.00%
6M+159.98%
1Y+315.86%
Valuation vs Sector

P/E of 25.17 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 11.6% over 5 years.
  • Profit CAGR of 57.0% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
25.17
Industry PE
39.97
Forward P/E est.
12.59
PEG Ratio
-
Book Value
₹496.56
Price to Book
3.64
P/S
3.14
EV/EBITDA
14.99
Dividend Yield
0.58%

Growth (CAGR)

Revenue 5Y
11.62%
Profit 5Y
56.99%
Revenue (YoY)
17.88%
Earnings (YoY)
126.84%

Profitability & Returns

ROCE
19.39%
ROE
15.48%
ROA
12.04%
Profit Margin
13.35%
Op Margin
15.80%
Gross Margin
49.68%
EPS (Latest Qtr)
₹35.53
EPS (TTM)
₹76.89

Balance Sheet & Liquidity

Debt/Equity
1.87
Quick Ratio
1.64
Current Ratio
2.44
Debt
₹12.41 Cr
Total Assets
₹853.70 Cr
Current Assets
₹395.20 Cr
Working Capital
₹233.44 Cr

Ownership

Promoter Holding
48.62%
Chg in Prom Hold
6.86%
FII / Inst Holding
1.16%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
₹2,586.51 Cr
Total Revenue (TTM)
₹769.60 Cr
EBITDA
₹159.87 Cr
Free Cash Flow
₹118.07 Cr
Operating Cash Flow
₹155.77 Cr
Shares Outstanding
₹1.34 Cr
Gross Margin
49.68%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 VENUSREM Venus Remedies Limited NSEPHARMA 1,935.00 25.17 ₹2,586.51 Cr 0.58% 19.39% 15.48% 11.62% 56.99%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 156.00 Cr95.00 Cr168.00 Cr143.00 Cr195.00 Cr109.00 Cr170.00 Cr177.00 Cr197.66 Cr131.90 Cr192.75 Cr180.26 Cr259.40 Cr
Cost of Revenue --------103.06 Cr74.15 Cr107.31 Cr86.25 Cr119.56 Cr
Gross Profit --------94.60 Cr57.75 Cr85.44 Cr94.01 Cr139.84 Cr
Operating Expenses 131.00 Cr85.00 Cr150.00 Cr131.00 Cr176.00 Cr97.00 Cr163.00 Cr158.00 Cr67.62 Cr53.83 Cr60.65 Cr63.05 Cr83.18 Cr
Operating Income 17.00 Cr2.00 Cr12.00 Cr5.00 Cr13.00 Cr5.00 Cr2.00 Cr13.00 Cr26.98 Cr3.92 Cr24.79 Cr30.96 Cr56.66 Cr
EBITDA 25.00 Cr10.00 Cr18.00 Cr12.00 Cr19.00 Cr11.00 Cr8.00 Cr18.00 Cr35.76 Cr18.79 Cr32.67 Cr40.04 Cr68.38 Cr
Interest Expense 000000001.00 L1.00 L1.00 L1.00 L1.00 L
Pretax Income 20.00 Cr5.00 Cr14.00 Cr8.00 Cr17.00 Cr7.00 Cr9.00 Cr25.00 Cr31.04 Cr12.60 Cr26.49 Cr33.47 Cr61.61 Cr
Tax Provision 8.80 Cr3.85 Cr4.34 Cr96.00 L6.80 Cr5.74 Cr5.49 Cr5.25 Cr10.04 Cr3.01 Cr6.36 Cr7.89 Cr14.11 Cr
Net Income 11.00 Cr1.00 Cr10.00 Cr7.00 Cr11.00 Cr1.00 Cr4.00 Cr20.00 Cr21.00 Cr9.60 Cr20.13 Cr25.58 Cr47.49 Cr
Diluted EPS 8.270.887.445.127.860.912.6314.6615.717.1815.0619.1435.53

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 455.00 Cr407.00 Cr400.00 Cr372.00 Cr322.00 Cr335.00 Cr544.00 Cr-553.38 Cr591.45 Cr652.89 Cr769.60 Cr
Cost of Revenue --------345.36 Cr373.19 Cr378.62 Cr387.27 Cr
Gross Profit --------208.02 Cr218.26 Cr274.27 Cr382.33 Cr
Operating Expenses 366.00 Cr326.00 Cr349.00 Cr333.00 Cr289.00 Cr295.00 Cr490.00 Cr-180.29 Cr185.10 Cr228.24 Cr260.72 Cr
Operating Income 43.00 Cr39.00 Cr11.00 Cr5.00 Cr-1.00 Cr9.00 Cr19.00 Cr-27.73 Cr33.16 Cr46.03 Cr121.61 Cr
EBITDA 89.00 Cr81.00 Cr51.00 Cr39.00 Cr33.00 Cr41.00 Cr54.00 Cr-70.35 Cr71.18 Cr94.40 Cr159.87 Cr
Interest Expense 41.00 Cr38.00 Cr34.00 Cr35.00 Cr25.00 Cr13.00 Cr13.00 Cr-11.80 L9.37 L7.00 L4.00 L
Pretax Income 3.00 Cr4.00 Cr-22.00 Cr-28.00 Cr-30.00 Cr-8.00 Cr49.00 Cr-37.93 Cr44.64 Cr71.82 Cr134.16 Cr
Tax Provision -2.85 Cr2.08 Cr4.62 Cr-3.08 Cr1.20 Cr-1.92 Cr-13.23 Cr-11.36 Cr16.15 Cr26.51 Cr30.87 Cr
Net Income 5.00 Cr2.00 Cr-17.00 Cr-31.00 Cr-29.00 Cr-10.00 Cr62.00 Cr-26.57 Cr28.49 Cr45.31 Cr102.78 Cr
Diluted EPS 4.511.49-13.84-24.87-23.15-8.1050.05-19.8821.3133.8976.89

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 841.00 Cr843.00 Cr765.00 Cr751.00 Cr733.00 Cr644.00 Cr556.00 Cr-601.08 Cr626.82 Cr715.72 Cr853.70 Cr
Current Assets --------322.83 Cr359.52 Cr451.72 Cr395.20 Cr
Cash & Equivalents --------21.21 Cr48.96 Cr57.52 Cr25.12 Cr
Inventory --------119.94 Cr121.69 Cr100.49 Cr129.37 Cr
Receivables --------76.66 Cr80.50 Cr112.22 Cr103.28 Cr
Total Liabilities --------140.74 Cr139.27 Cr154.77 Cr189.95 Cr
Current Liabilities --------82.57 Cr79.42 Cr136.29 Cr161.76 Cr
Long Term Debt -------38.68 Cr38.68 Cr38.68 Cr0-
Total Debt 321.00 Cr335.00 Cr312.00 Cr307.00 Cr298.00 Cr220.00 Cr51.00 Cr-42.29 Cr41.33 Cr1.69 Cr12.41 Cr
Total Equity 456.00 Cr437.00 Cr388.00 Cr362.00 Cr332.00 Cr323.00 Cr400.00 Cr-460.34 Cr487.55 Cr560.95 Cr663.75 Cr
Shares Outstanding --------1.34 Cr1.34 Cr1.34 Cr1.34 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 68.00 Cr47.00 Cr59.00 Cr31.00 Cr45.00 Cr78.00 Cr132.00 Cr-36.63 Cr37.29 Cr86.45 Cr155.77 Cr
Investing Cash Flow -67.00 Cr3.00 Cr-18.00 Cr8.00 Cr-11.00 Cr-5.00 Cr57.00 Cr--50.83 Cr-7.21 Cr-76.25 Cr-181.57 Cr
Financing Cash Flow -1.00 Cr-46.00 Cr-44.00 Cr-39.00 Cr-35.00 Cr-73.00 Cr-162.00 Cr--56.75 L-1.08 Cr-1.03 Cr-3.12 Cr
Capital Expenditure -9.00 Cr-1.00 Cr-18.00 Cr-12.00 Cr-10.00 Cr-8.00 Cr0--7.82 Cr-13.52 Cr-18.08 Cr-37.70 Cr
Free Cash Flow 59.00 Cr46.00 Cr41.00 Cr19.00 Cr35.00 Cr70.00 Cr132.00 Cr-28.81 Cr23.77 Cr68.37 Cr118.07 Cr
Net Change in Cash -1.00 Cr3.00 Cr-4.00 Cr0-1.00 Cr-027.00 Cr--14.77 Cr28.99 Cr9.17 Cr-28.92 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------37.6%36.9%42.0%49.7%
Operating Margin % 9.5%9.6%2.8%1.3%-0.3%2.7%3.5%-5.0%5.6%7.1%15.8%
Net Margin % 1.1%0.5%-4.2%-8.3%-9.0%-3.0%11.4%-4.8%4.8%6.9%13.4%
ROE % 1.1%0.5%-4.4%-8.6%-8.7%-3.1%15.5%-5.8%5.8%8.1%15.5%
ROCE % --------5.3%6.1%7.9%17.6%

Shareholding Pattern

Insiders
48.62%
Institutions
1.16%
Public Float
2.26%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VENUSREM

Google News hu, 21 May 2026

Does Venus Remedies (NSE:VENUSREM) Deserve A Spot On Your Watchlist? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxNaF8zMUZ2NlBoVXRMV1Jsb19tNm9tZmtUa1lPMllIdWJKVUN6UnIxMWJoZE9zUDRENTBEOTVCOENadGNPUmxIeFN0cnpCQnluc25nYVNCUkhrdVlFMjg3U2lwTDFqcG5HZVhBSzFvMUMtU0Y2SVdsX0pORkVmd1dULVJtdUVxX1NvTWVYdX…

Google News Wed, 12 Nov 2025

Venus Remedies Limited (NSE:VENUSREM) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxQN2hFQ3FZWXUwaVlBNHFFRFVkWDhONVMwYUVIN0xtQ1pRNXc0c0JUQ0RmY0prSVJ5TkkzSUxnYVpPTExoT2JqbXF3WkY2MFROSE9DNXUzb3J3UElDX0szTUJQQkJoYktCQVlaZGtpcTZPdVMwNXNpMVpFSU9tb1NWZlRjaXM5NjVwVEZ2NV…

Google News Fri, 26 Dec 2025

Venus Remedies Ltd - Equitypandit

<a href="https://news.google.com/rss/articles/CBMiY0FVX3lxTE9fNlIwSEI0VUktNzI5Y3dtTnpaeEdxX21hOFpoOGxiRDk0TDJ4ZWF2SnRBMjJoNmJLSTF0R2xzbzR0NElZUkN5ckt1SmpUd3JXeE9YMjNYUGZBNzh0N1F0UHpTbw?oc=5" target="_blank">Venus Remedies Ltd</a>&nbsp;&nbsp…

Google News Sat, 29 Jul 2017

VENUSREM Stock Price and Chart — NSE:VENUSREM - TradingView

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE9MUklORm9Ybm1vSHF2NnVrNGlPN3FlOEtGUnZGRDMwOHVhdWowQXJPMTZEOHpGanYxNzBadHBBNXp6ZHlfMUpUb0tsd1lhNzFtQXZreHNsY0owbDRiOXc?oc=5" target="_blank">VENUSREM Stock Price and Chart — NSE:VEN…

Google News Sun, 16 Nov 2025

Further Upside For Venus Remedies Limited (NSE:VENUSREM) Shares Could Introduce Price Risks After 25% Bounce - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxQUmc2Wk5CSGVnbVdiR2thYjhjaG5yQTNoOHhmc0M0aERVU0lBa1BVQUJsRm1BekZqSnhNVGxDNkdzTW5ldlZEM1NKVFpzYm9iakdIcFRSdlp1RW1OcXp0V0NPOHNIaUwtZ2ZMdkVLeUtLWm5DQXlMUVFlTTVnaWF2bE1WUmV1eThQX1FUUT…

Google News ue, 11 Aug 2020

VENUSREM.NS - Venus Remedies Limited Company Profile - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1ZbWZ2MTF4ODdNaDVIdTc3UGFTaDZDbklRQUh1TGFydjF3WDF3MDh6ZmlsczRRdWdXWVFJTzZ0UzhHVGlvdGhvcE1YY1NnRTVl?oc=5" target="_blank">VENUSREM.NS - Venus Remedies Limited Company Profile</a>&nb…

VENUSREM — Frequently Asked Questions

What is the current share price of Venus Remedies Limited (VENUSREM)?

As of 2026-07-15 09:52 IST, Venus Remedies Limited (VENUSREM) trades at ₹1,935.00 on NSE. Its 52-week range is ₹431.30 to ₹1,947.00.

What is the market capitalisation of VENUSREM?

Venus Remedies Limited (VENUSREM) has a market capitalisation of ₹2,586.51 Cr on NSE.

What is the P/E ratio of VENUSREM?

VENUSREM trades at a trailing price-to-earnings (P/E) ratio of 25.17. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 3.64.

Does VENUSREM pay a dividend?

Venus Remedies Limited (VENUSREM) currently offers a dividend yield of 0.58%.

What is the return on equity (ROE) of VENUSREM?

VENUSREM has a return on equity (ROE) of 15.48%. Its return on capital employed (ROCE) is 19.39%.

Is VENUSREM a good stock to buy?

This page provides a data-driven analysis of Venus Remedies Limited (VENUSREM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space